
|Articles|April 1, 2003
Time and the Bottom Line
Ponder this oh-so-common catch-22. Have you ever requested authorization from an insurance company to do a procedure on a patient and received a comment that they won't approve the procedure, but they will consider payment after the procedure has been performed? Or have your patients been denied approval when they have a medically necessary or medically related condition that should be legitimately approved?
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














